Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Rydapt (midostaurin) for the Treatment of Acute Myeloid Leukaemia and Systemic Mastocytosis

Drug (Brand / Generic)

Rydapt® / midostaurin

Developer

Novartis

Therapy Class

Multiple kinases inhibitor

Current Indication

Acute myeloid leukaemia (AML) and three types of systemic mastocytosis (SM) including aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated haematological neoplasm (SM-AHN) and mast cell leukaemia

Market Sector

Oncology

Development Status

Approved in the US
Expand

Go Top